SCHEMBL7429291

SCHEMBL7429291

CCCC(=O)Oc1ccc(C(=O)Cc2ccccc2)c([N+](=O)[O-])c1OC(=O)CCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL9 O00512 1/20 0.41
CTNNB1 P35222 1/20 0.41
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
KDM4E B2RXH2 1/20 0.38
RECQL P46063 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALOX15 P16050 1/20 0.38
CNR2 P34972 1/20 0.35
HIF1A Q16665 1/20 0.35
LMNA P02545 2/20 0.35
NCEH1 Q6PIU2 1/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
CRHBP P24387 1/20 0.34
HTT P42858 1/20 0.34
CRHR2 Q13324 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7429793 0.90 ABCB1 (0.42) BCL9CTNNB1KMT2AMEN1SMN1; SMN2
SCHEMBL7431099 0.88 BCL9 (0.39) BCL9CTNNB1KMT2AMEN1KDM4E
SCHEMBL6572279 0.84 BCL9 (0.43) BCL9CTNNB1KMT2AMEN1KDM4E
SCHEMBL7513057 0.84 PTPN1 (0.43) KMT2AMEN1KDM4ERECQLSMN1; SMN2
SCHEMBL7425246 0.82 MAPT (0.36) KMT2AMEN1SMN1; SMN2HIF1ALMNA
SCHEMBL7429307 0.78 BCL9 (0.41) BCL9CTNNB1KMT2AMEN1KDM4E
SCHEMBL7049743 0.77 BCL9 (0.41) BCL9CTNNB1KMT2AMEN1SMN1; SMN2
SCHEMBL5898877 0.74 LMNA (0.46) KMT2AMEN1KDM4ESMN1; SMN2ALOX15
SCHEMBL7429279 0.74 ABCB1 (0.47) KMT2AMEN1LMNATSHRALDH1A1
SCHEMBL7432671 0.73 NPC1 (0.41) KMT2AMEN1SMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & C.A., S.A. (PT) 2002-03-28 US claimed
EP-1167341-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them Portela & Ca., S.A. (PT) 2002-01-02 EP claimed
WO-2001098250-A1 SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PORTELA & CA SA (PT) 2001-12-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them SLC6A2, COMT, SLC6A3 BCL9 4557/4885CTNNB1 3047/4885KMT2A 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.